TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient interview with University of British Columbia researcher Cheryl Wellington discussed how cholesterol may relate to brain health and Alzheimer’s risk. Wellington said elevated LDL in midlife is associated with an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias, but the interview does not establish that cholesterol directly causes the diseases or that lowering it prevents them.
Cholesterol in midlife may matter to brain health through both blood-vessel effects and processes inside the brain, University of British Columbia researcher Cheryl Wellington said in a Being Patient interview. Wellington cited an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias associated with high LDL, while emphasizing the distinct roles of blood cholesterol and cholesterol within the brain.
Wellington, a professor and vice chair of research in the University of British Columbia’s Department of Pathology and Laboratory Medicine, studies cholesterol and transport proteins such as ApoE in relation to brain health. In the interview, she said the blood-brain barrier limits direct exchange between cholesterol in the bloodstream and cholesterol in the brain. That separation does not mean blood cholesterol is irrelevant: cholesterol may affect brain health through blood vessels, while cholesterol inside the brain has its own functions.
Wellington connected high LDL, often called “bad” cholesterol, with atherosclerosis, in which plaque builds up in arteries. Plaque in blood vessels supplying the brain may affect circulation, and she said atherosclerotic disease commonly occurs alongside Alzheimer’s pathology. She also described a separate kind of plaque: amyloid plaques, made of amyloid-beta, a protein naturally produced in the brain. The two forms of plaque are not the same.
The interview also discussed possible links between cholesterol handling in the brain’s immune cells, inflammation and the ApoE4 gene variant. Wellington said high LDL in midlife may interfere with the brain’s clearance of amyloid-beta. These points were presented as research-related explanations in a discussion, not as proof that cholesterol changes alone cause Alzheimer’s disease.
Midlife LDL and Brain Health
The discussion matters because LDL is a measurable cardiovascular risk factor, while dementia risk is shaped by multiple factors. Wellington’s account suggests one possible connection: blood-vessel health and brain processes may both be relevant to how cholesterol relates to neurological disease. The reported 7% to 9% estimate gives readers a sense of the association she described, but it should not be read as an individual prediction or as proof that lowering LDL will prevent dementia.
Wellington said reducing LDL to an appropriate range may reduce Alzheimer’s and other dementia risk, and argued that addressing cholesterol earlier could be more beneficial than waiting until symptoms emerge. The source material does not provide details of a specific clinical trial demonstrating that effect. People should discuss cholesterol measurements and treatment choices with a qualified health professional; the interview is not individualized medical advice.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
As an affiliate, we earn on qualifying purchases.
Two Cholesterol Systems
Cholesterol is present both in the bloodstream and in the brain, but the blood-brain barrier separates the two environments and restricts direct movement between them. Wellington’s explanation distinguishes cholesterol’s possible effects on blood vessels from its roles in brain cells and supporting cells. This distinction is central to understanding why a blood test does not directly measure cholesterol inside the brain.
Alzheimer’s disease is associated with amyloid plaques and another protein pathology, while atherosclerotic plaques form in blood vessels. Wellington said vascular disease often co-occurs with Alzheimer’s pathology. The interview also raised the role of ApoE, a protein involved in cholesterol transport, and the ApoE4 variant as a potential factor in how cholesterol buildup and inflammation affect the brain.
Being Patient identified the interview as a Live Talk produced with support from NewAmsterdam Pharma. The publication said the sponsor had no role in selecting guests, shaping questions or reviewing content before publication.
“Especially in people’s midlife years, high LDL increases the risk of Alzheimer’s disease and related dementias, estimated by about 7 to 9 percent.”
— Cheryl Wellington, University of British Columbia researcher
Limits of the Evidence
The interview does not identify the study or studies behind the 7% to 9% estimate, including the population studied, time period, or how the estimate was calculated. It therefore cannot establish how the figure applies to a particular person. The source also does not provide trial results showing that cholesterol-lowering treatment prevents Alzheimer’s disease or specify which treatments were considered.
The extent to which vascular effects, cholesterol processes inside the brain, ApoE4 and inflammation each contribute to dementia remains uncertain from the material provided. Alzheimer’s disease has multiple associated biological and risk factors, and the interview does not show that high LDL by itself causes the condition. The source material also gives no specific date for the interview’s publication.
What Research Must Establish
The next step for readers is to distinguish the interview’s explanation of possible mechanisms from evidence of treatment benefit. Further research would need to clarify how midlife LDL relates to later dementia risk, how that association varies among people, and whether lowering LDL changes the likelihood of developing Alzheimer’s disease or related dementias.
For now, Wellington’s practical point was to check LDL and discuss levels with a physician. The source provides no new guideline, treatment recommendation or announced study milestone. People considering cholesterol treatment should make decisions with a qualified clinician based on their health circumstances, rather than treating dementia prevention as an established outcome of any particular intervention.
Key Questions
Does high LDL cause Alzheimer’s disease?
The interview describes an association between high LDL, particularly in midlife, and higher dementia risk. It does not establish that high LDL directly causes Alzheimer’s disease.
How much higher was the risk estimate Wellington cited?
Wellington cited an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias for people with high LDL in midlife. The supplied material does not specify the study, population or calculation behind that estimate.
Is cholesterol in the blood the same as cholesterol in the brain?
No. Wellington said the blood-brain barrier limits direct exchange between the two. Blood cholesterol may affect vessels, while cholesterol within the brain has separate roles.
Does lowering cholesterol prevent dementia?
The interview does not establish that cholesterol-lowering treatment prevents dementia. Wellington said bringing LDL into range may reduce risk, but the provided material includes no clinical trial results proving a preventive effect.
What should someone do about a high LDL result?
Discuss the result and possible next steps with a qualified health professional. The interview is general reporting, not personalized medical advice.
Source: beingpatient.com
